New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
06:01 EDTXOMAXOMA weakness a buying opportunity, says Piper Jaffray
Piper Jaffray recommends buying shares of XOMA on weakness after the company announced that the 6-month Phase II data of gevokizumab in Erosive Osteoarthritis of the Hand failed to support further development. Piper said it had no value of this indication in its $9 price target and reiterates an Overweight rating on the name.
News For XOMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 16, 2014
07:23 EDTXOMAIBF Conferences to hold a summit
Ophthalmology Innovation Summit is being held in Chicago on October 16.
October 10, 2014
13:01 EDTXOMAXOMA management to meet with Maxim
Subscribe for More Information
October 9, 2014
09:08 EDTXOMAXOMA initiates dosing in XOMA 358 Phase 1 study
Subscribe for More Information
October 6, 2014
13:01 EDTXOMAXOMA, Texas A&M University System agree to non-exclusive license
The Texas A&M University System and XOMA announced that the Texas A&M University System agreed to a non-exclusive license for XOMA's innovative design of a manufacturing facility. The patented technology relates to an arrangement of mobile clean rooms within the manufacturing facility with each MCR providing a portable, self-contained environment that allows for drug development. The A&M System will use MCRs for certain government programs at The National Center for Therapeutics Manufacturing facility. Details of the license were not disclosed.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use